Cerezo-Manchado Juan José, Navarro-Almenzar Begoña, Elvira-Ruiz Ginés, García-Candel Faustino, Flores-Blanco Pedro José, Caro-Martínez Cesar, Manzano-Fernández Sergio, García-Iniesta Natalia, Sánchez-García Javier, Cabañas-Perianes Valentín, Moraleda-Jiménez José María
Servicio de Hematología y Hemoterapia, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain.
Servicio de Cardiología, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain.
Future Cardiol. 2018 May;14(3s):31-37. doi: 10.2217/fca-2018-0024.
To evaluate the clinical profile and effectiveness/safety of patients taking rivaroxaban in clinical practice.
Retrospective study that included patients with nonvalvular atrial fibrillation treated with rivaroxaban for the prevention of stroke between January 2012 and December 2016 in a tertiary hospital in Spain.
A total of 142 patients (median age 78 years, 40.1% men, 32.4% creatinine clearance <50 ml/min; 96.5% CHADS-VASc ≥2; 44.3% HAS-BLED ≥3) were included. Only two patients had a thromboembolic event (in both cases ischemic stroke) and three patients had major bleeding (rates of 1.3 and 1.9 events/100 patient years, respectively).
Data regarding effectiveness and safety in our cohort were consistent with previous studies, showing that rivaroxaban can be effective and safely used in our setting.
评估在临床实践中服用利伐沙班的患者的临床特征及有效性/安全性。
一项回顾性研究，纳入了2012年1月至2016年12月在西班牙一家三级医院接受利伐沙班治疗以预防卒中的非瓣膜性心房颤动患者。
共纳入142例患者（中位年龄78岁，男性占40.1%，32.4%的患者肌酐清除率<50 ml/min；96.5%的患者CHADS-VASc评分≥2；44.3%的患者HAS-BLED评分≥3）。仅有2例患者发生血栓栓塞事件（均为缺血性卒中），3例患者发生大出血（发生率分别为1.3和1.9事件/100患者年）。
我们队列中关于有效性和安全性的数据与先前研究一致，表明利伐沙班在我们的研究环境中可有效且安全地使用。
